Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 10/20 | 0.59 |
| ▸ | MMP13 | P45452 | 9/20 | 0.59 |
| ▸ | MMP9 | P14780 | 8/20 | 0.59 |
| ▸ | MMP1 | P03956 | 7/20 | 0.59 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7006613 | 0.85 | MMP1 (0.57) | ADAM17MMP13MMP9MMP1NR3C1 | |
| SCHEMBL6290579 | 0.84 | MMP1 (0.53) | ADAM17MMP13MMP9MMP1NR3C1 | |
| SCHEMBL6290046 | 0.82 | ADAM17 (0.59) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL6290514 | 0.82 | ADAM17 (0.59) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL6289947 | 0.80 | MMP13 (0.82) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL7008676 | 0.76 | LMNA (0.66) | ADAM17MMP13MMP9MMP1NR3C1 | |
| SCHEMBL6290687 | 0.76 | LMNA (0.56) | ADAM17MMP13MMP9MMP1NR3C1 | |
| SCHEMBL7093617 | 0.75 | ADAM17 (0.61) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL6293369 | 0.75 | ADAM17 (0.60) | ADAM17MMP13MMP9MMP1 | |
| SCHEMBL6811146 | 0.74 | ADAM17 (0.57) | ADAM17MMP13MMP9MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946473-B2 | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | WYETH HOLDINGS CORPORATION (US) | 2005-09-20 | — | — | US | disclosed |
| US-20030208066-A1 | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | AMERICAN CYANAMID COMPANY | 2003-11-06 | — | — | US | disclosed |
| EP-1279674-A2 | Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | American Cyanamid Company (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-1157024-B1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | AMERICAN CYANAMID CO (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1157024-A1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | American Cyanamid Company (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000044749-A1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208066-A1 | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | SI, TNF, PTDSS1 | ADAM17 67/4885MMP13 334/4885MMP9 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.